MedTrace Logo

Effect of Liraglutide on Neural Responses to High Fructose Corn Syrup in Individuals With Obesity.

NCT03500484 · Status: TERMINATED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2024-07-16

Study results available
· View outcomes & findings →

Summary

To study the effects of liraglutide on neural responses to high fructose corn syrup (HFCS) in individuals with obesity.

Conditions

  • Obesity, Childhood
  • Neural Development

Interventions

DRUG

Liraglutide

Liraglutide will be supplied in the following package sizes containing disposable, pre-filled, multidose pens. Each individual pen delivers doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg or 3 mg (6 mg/mL, 3 mL). Liraglutide will be self-administered daily for 12 weeks under the following regimen: 0.6mg for 1 week, 1.2mg for 1 week, 1.8mg for 1 week, 2.4mg for 1 week, 3.0mg until week 12.

Sponsors & Collaborators

  • Yale University

    lead OTHER

Principal Investigators

  • Ania Jastreboff, Phd,MD · Yale University

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
39 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-06-06
Primary Completion
2020-06-25
Completion
2020-06-25
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03500484 on ClinicalTrials.gov